Pre-Treatment and Post-Treatment Neutrophil-to-Lymphocyte Ratio Predict Pathological Tumor Response and Survival in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

被引:0
作者
Delikgoz Soykut, Ela [1 ]
Kemal, Yasemin [2 ]
Odabasi, Eylem [1 ]
Sahin, Nilgun [1 ]
Keskinkilic Yagiz, Betul [3 ]
Yazicioglu, Irem Melike [4 ]
Aytac Arslan, Suheyla [5 ]
Guney, Vildiz [5 ]
机构
[1] Univ Hlth Sci, Samsun Training & Res Hosp, Dept Radiat Oncol, Samsun, Turkey
[2] Istinye Univ, Dept Med Oncol, Istanbul, Turkey
[3] Gazi State Hosp, Dept Gen Surg, Samsun, Turkey
[4] Univ Hlth Sci, Samsun Training & Res Hosp, Dept Pathol, Samsun, Turkey
[5] Mem Hosp, Dept Radiat Oncol, Ankara, Turkey
来源
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2022年 / 37卷 / 02期
关键词
Neoadjuvant chemoradiotherapy; neutrophil-to-lymphocyte ratio; pathological tumor response; prognosis; rectal cancer; survival; SYSTEMIC INFLAMMATORY RESPONSE; PREOPERATIVE CHEMORADIOTHERAPY; CHEMORADIATION; MULTICENTER; OUTCOMES;
D O I
10.5505/tjo.2022.3467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of this study is to investigate the relationship between baseline and post-treatment neutrophil-to-lymphocyte ratio (NLR) levels and response to neoadjuvant chemoradiotherapy (CRT) in terms of good pathological response and survival. METHODS Fifty-six patients who underwent neoadjuvant CRT and curative surgery for locally advanced rectal cancer (LARC) were analyzed retrospectively. Pre-CRT and post-CRT hematologic parameters were recorded. The link between NLR and clinical outcomes was explored. RESULTS The receiver operating characteristic analysis revealed appropriate cut-off values of 2.87 for pre-CRT NLR associated with good pathological response and 8.68 for post-CRT NLR predicting survival. The low pre-CRT NLR group had better outcomes in terms of good pathological response compared to the high pre-CRT NLA group (OR 4.15, 95% CI 1.23-13.76, p=0.021). However, the analysis failed to show the correlation between NLR and pCR (OR 2.74, 95% CI 0.37-20.15, p=0.320). Patients with elevated post-CRT NLR had significantly worse 5-year overall survival (OS), disease-free survival (DFS) and local regional recurrence-free survival (LRRFS) rates compared to low post-CRT NLR in multivariate analysis (46.6% vs. 74.4%, p=0.020; 35.3% vs. 71.9%, p=0.018; 40.8% vs. 78.1%, p=0.006). CONCLUSION High pre-CRT NLR might be used as a poor pathological tumor response predictor in LARC patients treated with neoadjuvant CRT. In addition, low post-CRT NLR is associated with favorable OS, DFS, and LRRFS. Therefore, easily accessible and cost-effective NLR can be considered as a potential predictive marker to identify patients and establish personalized treatment strategies.
引用
收藏
页码:139 / 149
页数:11
相关论文
共 50 条
  • [21] Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy
    Barrington, David A.
    Calo, Corinne
    Baek, Jae
    Brown, Morgan
    Wagner, Vincent
    Gonzalez, Lynette
    Huffman, Allison
    Benedict, Jason
    Bixel, Kristin
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 522 - 529
  • [22] The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma
    Medine Kara
    Sema Uysal
    Uğur Altinişik
    Sibel Cevizci
    Oğuz Güçlü
    Fevzi Sefa Dereköy
    European Archives of Oto-Rhino-Laryngology, 2017, 274 : 535 - 542
  • [23] Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer
    Yoo, Eun Jin
    Park, Jun Chul
    Kim, Eun Hye
    Park, Chan Hyuk
    Shim, Choong Nam
    Lee, Hyun Jik
    Chung, Hyun Soo
    Lee, Hyuk
    Shin, Sung Kwan
    Lee, Sang Kil
    Lee, Chang Geol
    Lee, Yong Chan
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (09) : 846 - 853
  • [24] The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy
    Wang, Duoying
    Guo, Dong
    Li, Aijie
    Wang, Peiliang
    Teng, Feifei
    Yu, Jinming
    FUTURE ONCOLOGY, 2020, 16 (09) : 439 - 449
  • [25] Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma
    Yersal, Ozlem
    Odabasi, Eylem
    Ozdemir, Ozge
    Kemal, Yasemin
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (04) : 453 - 458
  • [26] Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis
    Colloca, Giuseppe
    Venturino, Antonella
    Guarneri, Domenico
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (04) : 421 - 429
  • [27] Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
    Anand, Santhosh
    Bhati, Gajendra
    Gurram, Ramprakash
    Gnanasekaran, Senthil
    Kate, Vikram
    Pottakkat, Biju
    Kalayarasan, Raja
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (02) : 659 - 665
  • [28] The prognostic role of the change in albumin-derived neutrophil-to-lymphocyte ratio during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    Pan, Zhen
    Wang, Ye
    Li, Shoufeng
    Cai, Huajun
    Guan, Guoxian
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (03): : 612 - 624
  • [29] The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy
    Cui, Jian
    Yang, Lin
    Guo, Lei
    Shao, Yongfu
    Tan, Dongfeng
    Li, Ni
    Zhang, Haizeng
    ONCOTARGET, 2017, 8 (23) : 37845 - 37854
  • [30] Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients
    Guo, Dong
    Han, Anqin
    Jing, Wang
    Chen, Dawei
    Jin, Feng
    Li, Minghuan
    Kong, Li
    Yu, Jinming
    FUTURE ONCOLOGY, 2018, 14 (12) : 1187 - 1196